Daiichi Sankyo Company, Limited (DSKYF) 是一家上市公司 屬於 醫療保健 板塊,經營於 制药 - 綜合 產業. 公司總部位於 Tokyo, 日本. 現任CEO為 Hiroyuki Okuzawa.
DSKYF 擁有 IPO日期為 2008-06-24, 18,726 名全職員工, 在 Other OTC, 市值為 $32.23B.
Daiichi Sankyo Company, Limited is a Tokyo-based pharmaceutical company founded in 1899 that researches, develops, manufactures, and markets a diverse portfolio of prescription and over-the-counter medicines globally. The company's core therapeutic areas include oncology, cardiovascular disease, diabetes, pain management, and infectious disease, with key products such as Enhertu (trastuzumab deruxtecan) for cancer treatment, edoxaban for anticoagulation, and teneligliptin for diabetes management. Beyond pharmaceuticals, Daiichi Sankyo operates across consumer health, vaccines, animal health, cosmetics, and medical devices. The company has established strategic collaborations, including a partnership with Guardant Health to develop companion diagnostics, and maintains a strong commitment to innovation across multiple healthcare segments.